The Medicines Company, Boston Scientific announce co-promotion agreement for Promus PREMIER stent system

Published on December 6, 2013 at 8:57 AM · No Comments

Boston Scientific Corporation (NYSE: BSX) and The Medicines Company (NASDAQ: MDCO) announce a co-promotion agreement for the Boston Scientific Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent System. Under the terms of the agreement, The Medicines Company's acute cardiovascular care sales force will collaborate with the Boston Scientific Interventional Cardiology sales force to provide promotional support for the Promus PREMIER Stent System in U.S. hospitals beginning January 1, 2014.

The Promus PREMIER Stent System, the latest Boston Scientific FDA-approved drug-eluting stent (DES), offers physicians improved performance in treating patients with coronary artery disease.  It features a unique, customized platinum chromium alloy stent architecture, combined with the market-leading Everolimus drug, a biocompatible, fluorinated co-polymer, and an enhanced stent delivery system. Coronary artery disease is a narrowing of blood vessels that supply blood and oxygen to the heart.  Patients with coronary artery disease may experience chest pain, shortness of breath and fatigue, and may also be at risk for a heart attack. One established treatment option is the placement of a stent in the artery to help keep it open and allow the blood to flow more freely.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post